Development of a New Malaria Treatment Tablet
Author Information
Author(s): Catherine Lacaze, Tina Kauss, Jean-René Kiechel, Antonella Caminiti, Fawaz Fawaz, Laurent Terrassin, Sylvie Cuart, Luc Grislain, Visweswaran Navaratnam, Bellabes Ghezzoul, Karen Gaudin, Nick J White, Piero L Olliaro, Pascal Millet
Primary Institution: Ellipse Pharmaceuticals, Pessac, France
Hypothesis
Can a stable co-formulation of artesunate and amodiaquine be developed in a bilayer tablet for malaria treatment?
Conclusion
The collaboration between research and industry led to the successful development of a stable bilayer tablet for malaria treatment.
Supporting Evidence
- The bilayer tablet formulation successfully isolated the two active ingredients to prevent degradation.
- Long-term stability studies showed the bilayer tablets maintained their drug content over time.
- The project was a collaboration between multiple institutions, enhancing the development process.
Takeaway
Scientists worked together to create a new medicine for malaria that keeps the ingredients separate so they don't spoil. This makes it safer and easier to use.
Methodology
Pharmaceutical development involved pre-formulation studies, stability testing, and collaboration between various research and industrial partners.
Limitations
Lack of public funding was a significant obstacle in the development process.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website